Reuters logo
BRIEF-Astrazeneca provides Tralokinumab update in severe asthma​
November 1, 2017 / 7:41 AM / 23 days ago

BRIEF-Astrazeneca provides Tralokinumab update in severe asthma​

Nov 1 (Reuters) - Astrazeneca Plc:

* ASTRAZENECA TRALOKINUMAB UPDATE IN SEVERE ASTHMA​

* ANNOUNCED TOP-LINE RESULTS OF PHASE III STRATOS 2, TROPOS TRIALS FOR TRALOKINUMAB

* ‍IN STRATOS 2, TRALOKINUMAB DID NOT ACHIEVE A STATISTICALLY-SIGNIFICANT REDUCTION IN ANNUAL ASTHMA EXACERBATION RATE (AAER), PRIMARY ENDPOINT

* ‍IN TROPOS, TRALOKINUMAB DIDN‘T ACHIEVE STATISTICALLY-SIGNIFICANT REDUCTION IN ORAL CORTICOSTEROID (OCS) USE, PRIMARY ENDPOINT

* ‍SAFETY AND TOLERABILITY FINDINGS IN STRATOS 2 AND TROPOS WERE CONSISTENT WITH THOSE OBSERVED IN PREVIOUS TRIALS WITH TRALOKINUMAB​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below